.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Claims for Patent: 7,399,787

« Back to Dashboard

Claims for Patent: 7,399,787

Title:Methods of treating cancer with HDAC inhibitors
Abstract:The present invention provides methods of treating cancers, chemoprevention, selectively inducing terminal differentiation, cell growth arrest and/or apoptosis of neoplastic cells, and/or inhibiting histone deacetylase (HDAC) by administration of pharmaceutical compositions comprising potent HDAC inhibitors. The oral bioavailability of the active compounds in the pharmaceutical compositions of the present invention is surprisingly high. Moreover, the pharmaceutical compositions unexpectedly give rise to high, therapeutically effective blood levels of the active compounds over an extended period of time. The present invention further provides a safe, daily dosing regimen of these pharmaceutical compositions, which is easy to follow, and which results in a therapeutically effective amount of the HDAC inhibitors in vivo.
Inventor(s): Chiao; Judy H. (Berkeley Heights, NJ), Bacopoulos; Nicholas G. (New York, NY), Miller; Thomas A. (New York, NY), Paradise; Carolyn M. (Cortland Manor, NY), Richon; Victoria M. (Rye, NY)
Assignee: Merck HDAC Research, LLC (Boston, MA)
Application Number:10/616,649
Patent Claims: 1. A method of treating cutaneous T-cell lymphoma in a subject, said method comprising the step of orally administering to the subject a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA) or a pharmaceutically acceptable salt or hydrate thereof, represented by the structure: ##STR00057## and a pharmaceutically acceptable carrier or diluent, wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is administered daily at a dose of 400 mg once a day.

2. The method of claim 1, wherein said composition is contained within a gelatin capsule.

3. The method of claim 1, wherein said carrier or diluent is microcrystalline cellulose.

4. The method of claim 1, wherein said composition further comprises sodium croscarmellose as a disintegrating agent.

5. The method of claim 1, wherein said composition further comprises magnesium stearate as a lubricant.

6. A method of treating cutaneous T-cell lymphoma in a subject, which method comprises the step of orally administering to the subject a pharmaceutical composition comprising suberoylanilide hydroxamic acid (SAHA), represented by the structure: ##STR00058## or a pharmaceutically acceptable salt or hydrate thereof and a pharmaceutically acceptable carrier or diluent, and wherein the SAHA or the pharmaceutically acceptable salt or hydrate thereof is administered at a dose of 300 mg twice daily on a schedule of daily administration for two consecutive weeks, then no administration for one week.

7. The method of claim 6, wherein said composition is contained within a gelatin capsule.

8. The method of claim 7, wherein said carrier or diluent is microcrystalline cellulose.

9. The method of claim 8, wherein said composition further comprises sodium croscarmellose as a disintegrating agent.

10. The method of claim 9, wherein said composition further comprises magnesium stearate as a lubricant.

11. The method according to claim 1 or claim 6, wherein said pharmaceutical composition comprises SAHA as the active ingredient.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc